Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide.

Literature DB >> 21902593

Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide.

Abstract

Since the RV144 vaccine combination showed efficacy in a Phase III trial, it provides an opportunity to generate hypotheses about the immune responses necessary for protection against HIV-1 infection, and these results could help devise vaccine candidates with higher efficacy. Here we describe how researchers can determine the correlates of immune protection for an HIV/AIDS vaccine, particularly in the context of the RV144 trial, and we discuss the terminology used to describe correlates and surrogates.

Entities: Chemical Disease

Mesh：

Substances：

Year: 2011 PMID： 21902593 PMCID： PMC3316118 DOI： 10.1089/aid.2011.0240

Source DB: PubMed Journal: AIDS Res Hum Retroviruses ISSN： 0889-2229 Impact factor: 2.205

13 in total

1. Exposure stratified case-cohort designs.

Authors: O Borgan; B Langholz; S O Samuelsen; L Goldstein; J Pogoda
Journal: Lifetime Data Anal Date: 2000-03 Impact factor: 1.588

2. Principal stratification in causal inference.

Authors: Constantine E Frangakis; Donald B Rubin
Journal: Biometrics Date: 2002-03 Impact factor: 2.571

3. ASSESSING SURROGATE ENDPOINTS IN VACCINE TRIALS WITH CASE-COHORT SAMPLING AND THE COX MODEL.

Authors: Li Qin; Peter B Gilbert; Dean Follmann; Dongfeng Li
Journal: Ann Appl Stat Date: 2008-03 Impact factor: 2.083

4. Response to Andrew Dunning's comment on 'evaluating a surrogate endpoint at three levels, with application to vaccine development'.

Authors: Peter B Gilbert; Li Qin; Steven G Self
Journal: Stat Med Date: 2009-02-15 Impact factor: 2.373

Review 5. Vaccines: correlates of vaccine-induced immunity.

Authors: Stanley A Plotkin
Journal: Clin Infect Dis Date: 2008-08-01 Impact factor: 9.079

6. A framework for assessing immunological correlates of protection in vaccine trials.

Authors: Li Qin; Peter B Gilbert; Lawrence Corey; M Juliana McElrath; Steven G Self
Journal: J Infect Dis Date: 2007-10-02 Impact factor: 5.226

7. Surrogate endpoints in clinical trials: definition and operational criteria.

Authors: R L Prentice
Journal: Stat Med Date: 1989-04 Impact factor: 2.373

8. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial.

Authors: Peter B Gilbert; Michael L Peterson; Dean Follmann; Michael G Hudgens; Donald P Francis; Marc Gurwith; William L Heyward; David V Jobes; Vladimir Popovic; Steven G Self; Faruk Sinangil; Donald Burke; Phillip W Berman
Journal: J Infect Dis Date: 2005-01-27 Impact factor: 5.226

9. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate.

Authors: Donald N Forthal; Peter B Gilbert; Gary Landucci; Tran Phan
Journal: J Immunol Date: 2007-05-15 Impact factor: 5.422

10. Statistical identifiability and the surrogate endpoint problem, with application to vaccine trials.

Authors: Julian Wolfson; Peter Gilbert
Journal: Biometrics Date: 2010-12 Impact factor: 2.571

22 in total

1. Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

Authors: Barton F Haynes; Peter B Gilbert; M Juliana McElrath; Susan Zolla-Pazner; Georgia D Tomaras; S Munir Alam; David T Evans; David C Montefiori; Chitraporn Karnasuta; Ruengpueng Sutthent; Hua-Xin Liao; Anthony L DeVico; George K Lewis; Constance Williams; Abraham Pinter; Youyi Fong; Holly Janes; Allan DeCamp; Yunda Huang; Mangala Rao; Erik Billings; Nicos Karasavvas; Merlin L Robb; Viseth Ngauy; Mark S de Souza; Robert Paris; Guido Ferrari; Robert T Bailer; Kelly A Soderberg; Charla Andrews; Phillip W Berman; Nicole Frahm; Stephen C De Rosa; Michael D Alpert; Nicole L Yates; Xiaoying Shen; Richard A Koup; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Nelson L Michael; Jerome H Kim
Journal: N Engl J Med Date: 2012-04-05 Impact factor: 91.245

2. Combining biomarkers for classification with covariate adjustment.

Authors: Soyoung Kim; Ying Huang
Journal: Stat Med Date: 2017-03-09 Impact factor: 2.373

Review 3. Systems vaccinology: its promise and challenge for HIV vaccine development.

Authors: Helder I Nakaya; Bali Pulendran
Journal: Curr Opin HIV AIDS Date: 2012-01 Impact factor: 4.283

Review 4. Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies.

Authors: F Benjelloun; P Lawrence; B Verrier; C Genin; S Paul
Journal: J Virol Date: 2012-09-26 Impact factor: 5.103

5. Antibody responses to prime-boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140.

Authors: Kristel L Emmer; Lindsay Wieczorek; Steven Tuyishime; Sebastian Molnar; Victoria R Polonis; Hildegund C J Ertl
Journal: AIDS Date: 2016-10-23 Impact factor: 4.177